Key result
Sevoflurane has no clinically important effect on normal AV or accessory pathway conduction.
Why the study?
The effects of sevoflurane on the electrophysiologic properties of the human heart, including normal atrioventricular conduction and accessory pathways in Wolff-Parkinson-White syndrome, were unknown.
Does sevoflurane alter the electrophysiologic properties of the normal atrioventricular conduction system and accessory pathways in patients with Wolff-Parkinson-White syndrome?
Population
15 patients with Wolff-Parkinson-White syndrome undergoing elective radiofrequency catheter ablation
Comparison
Electrophysiologic measurements before and after sevoflurane administration during alfentanil/midazolam anesthesia
Design
Observational electrophysiologic study
Follow-up
Intraprocedural
Authors
Loading...
Sevoflurane appears suitable for WPW ablation without confounding EP mapping; supports use in this setting but leaves open need for larger trials.
Observational (n=15)
Does sevoflurane alter the electrophysiologic properties of the normal atrioventricular conduction system and accessory pathways in patients with Wolff-Parkinson-White syndrome?
Sevoflurane does not significantly alter the electrophysiologic properties of the AV node or accessory pathways, making it a suitable anesthetic agent for radiofrequency ablation in patients with Wolff-Parkinson-White syndrome.
Sharpe et al. (1999) conducted an observational in Wolff-Parkinson-White syndrome (n=15). Sevoflurane vs. Baseline (alfentanil/midazolam anesthesia alone) was evaluated on Electrophysiologic parameters of conduction in the normal atrioventricular conduction system or accessory pathway. Sevoflurane administration had no clinically important effect on the electrophysiologic parameters of conduction in the normal atrioventricular conduction system or accessory pathways.